Subscribe for email alerts

Don’t miss a single Science & Enterprise post. Sign up for our daily email alerts.

Follow us on Twitter

  • Scientists Finish the Human Genome at Last https://t.co/bTRwmNjHwP
    about 7 hours ago
  • While the public's attention for the past 18 months has been focused on Covid-19, the problem of opioid overdoses a… https://t.co/gr0q6FkShP
    about 1 day ago
  • New post on Science and Enterprise: Infographic – Drug Overdose Epidemic Accelerating https://t.co/rZP0zmFVgK #Science #Business
    about 1 day ago
  • "Unvaccinated people aren’t a random group of defectors who are trying to be deviant." @edyong209 talks to Dr. Rhea… https://t.co/FkzZWK83OE
    about 1 day ago
  • U.S. drops cases against five researchers accused of hiding ties to Chinese military https://t.co/0D4YvwvjZq
    about 2 days ago

Please share Science & Enterprise

Cypress Bioscience to Cut Business Lines, Slash Workforce

Cypress Bioscience in San Diego, California announced today several cost-cutting measures including a sharp reduction in staff. The steps announced will end a co-promotion agreement with Forest Laboratories, and close the company’s personalized testing services.

The drug development company discontinued an agreement with Forest Laboratories to co-promote Savella, its drug for fibromyalgia, a disorder causing pain in joints, muscles and other soft tissues. However, Cypress Bioscience will receive a $2 million payment from Forest Laboratories, and left open the possibility of future joint ventures.

The company will also discontinue or sell its personalized testing services in the field of rheumatology that provide physicians with information to help manage and optimize their patients’ care. Cypress Biosciences expects to cut its operating costs by about $10 million as a result, but expects to take $4.5 million in charges as well.

This restructuring will mean a staff reduction of 123 Cypress Bioscience employees, or 86 percent of its workforce.  The layoff will take effect on 6 October 2010.

Hat tip: Fierce Biotech

Comments are closed.